Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/139132ANTIMICROBIAL COMPOSITION AND PREPARATION METHOD THEREFOR, AND PRODUCT THEREOF
WO 30.06.2022
Int.Class A61K 33/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
14Alkali metal chlorides; Alkaline earth metal chlorides
Appl.No PCT/KR2021/013739 Applicant IHN, Dong Chul Inventor IHN, Dong Chul
The present invention relates to an antimicrobial composition and a preparation method therefor, and a product thereof, and, more specifically, to an antimicrobial composition comprising: 50-60 wt% of purified water; 1-10 wt% of a mixture comprising, in a ratio of 1:1 (50 wt% : 50 wt%), sodium chloride and calcium chloride from among chlorides; 1-2 wt% of a mixture comprising, in a ratio of 1:1 (50 wt% : 50 wt%), a Pueraria thunbergiana extract and a Platycodon grandiflorus extract from among natural extracts; 5-10 wt% of a mixture comprising, in a ratio of 1:1 (50 wt% : 50 wt%), sodium carbonate and sodium bicarbonate from among carbonates; 10-15 wt% of a mixture comprising, in a ratio of 1:1 (50 wt% : 50 wt%), lactic acid and acetic acid from among organic acids, and salts thereof; and 5-10 wt% of a mixture (undiluted solution) comprising chloric-acid-based compounds, which are inorganic acids, and thus the antimicrobial composition ensures the safety of fermentation technology, and increases absorption rate and efficacy in the body so that an excellent antibacterial or antiviral immune enhancement effect can be obtained through the synergistic effect of physiological actions.
2.WO/2022/139732DEVELOPMENT OF NANOMATERIAL FOR CONTROLLED RELEASE OF LUTEOLIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO 30.06.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/TR2021/051173 Applicant EGE ÜNİVERSİTESİ Inventor AKGÖL, Sinan
The invention relates to the development of nanomaterials for the controlled release of luteolin used in the treatment of neurodegenerative diseases.
3.WO/2022/140467TOPICAL COMPOSITIONS AND METHODS OF TREATING SKIN DISEASES AND CONDITIONS WITH SUCH COMPOSITIONS
WO 30.06.2022
Int.Class A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Appl.No PCT/US2021/064729 Applicant SAMSON PHARMA, LLC Inventor DURRANI, Manzer J.
A pharmaceutical composition is provided including tamibarotene or a salt or analog thereof, a solubilizer, a permeation enhancer, a polymeric emulsifier, and a surfactant. In a further preferred embodiment, the pharmaceutical composition is in the form of a gel or cream, and provides a smooth composition to apply to the skin. The invention is further directed to methods of manufacturing the pharmaceutical composition and methods of treating a patient's skin with the pharmaceutical composition.
4.WO/2022/1405276-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS
WO 30.06.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2021/064830 Applicant AJAX THERAPEUTICS, INC. Inventor MASSE, Craig E.
The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
5.WO/2022/136417PULSATIVE GNRH ADMINISTRATION FOR TREATING FOOD INTAKE RELATED DISORDERS
WO 30.06.2022
Int.Class A61K 38/09
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
09Luteinising hormone-releasing hormone ; Related peptides
Appl.No PCT/EP2021/087066 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor PREVOT, Vincent
The present invention relates to the pulsatile administration of the gonadotropin- releasing hormone (GnRH) for the treatment of food intake related disorder related disorder such as obesity (overeating) and anorexia (undereating). The inventors demonstrated that a population of mutant mice expressing BoNT/B in GnRH neurons (Gnrh::cre;iBot overweight), in which the GnRH release is inhibited, did not only fail to reach puberty onset and showed hypogonadotropic hypogonadism, but also developed overweight and hyperleptinemia. Unexpectedly, they found that the increase in body weight in mutant mice persisted in adulthood despite a significant decrease in food intake. Using a mouse model of obesity inventors observed an altered pattern of pulsatile LH secretion and that the frequency of LH pulses is inversely correlated to body weight and adiposity demonstrating that the heavier the animals were getting the more the GnRH/LH pulsatile pattern was altered. The present inventors further demonstrated that pulsatile GnRH treatment can allow to restore a control/lean pattern of GnRH/LH release in obese mice, and that this pulsatile administration of a "lean pattern" of native GnRH peptide in obese mice normalized their cumulative food intake to levels comparable with lean mice.
6.WO/2022/136912TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EGFR DOWNSTREAM EFFECTORS - INDUCED REACTIONS
WO 30.06.2022
Int.Class A61K 31/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
Appl.No PCT/IB2021/000799 Applicant LUTRIS PHARMA LTD. Inventor SHELACH, Noa
Pharmaceutical topical compositions comprising compound of Formula IV and method of using pharmaceutical topical compositions comprising compound of Formula IV for the treatment or prevention of EGFR inhibitor, PI3K inhibitor, MEK inhibitor and/or HER dimerization inhibitor-induced acneiform lesions in a subject in need thereof are provided.
7.WO/2022/140647MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
WO 30.06.2022
Int.Class A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Appl.No PCT/US2021/065037 Applicant CHILDREN'S HOSPITAL MEDICAL CENTER Inventor HOYT, Scott Bryan
Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
8.WO/2022/140677COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS
WO 30.06.2022
Int.Class C07C 211/38
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
211Compounds containing amino groups bound to a carbon skeleton
33having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
34of a saturated carbon skeleton
38containing condensed ring systems
Appl.No PCT/US2021/065090 Applicant THE BROAD INSTITUTE, INC. Inventor CHAMBERLAIN, Brian, T.
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
9.WO/2022/140317SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT
WO 30.06.2022
Int.Class C07D 211/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
56Nitrogen atoms
58attached in position 4
Appl.No PCT/US2021/064484 Applicant ALKERMES, INC. Inventor PENNINGTON, Lewis, D.
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
10.WO/2022/134332USE OF ALOESIN IN PREPARATION OF PRODUCT FOR PREVENTING OR TREATING OBESITY
WO 30.06.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/CN2021/082124 Applicant HAINAN MEDICAL UNIVERSITY Inventor WANG, Yan
The use of aloesin in the preparation of a product for preventing or treating obesity. Aloesin can inhibit lipid accumulation, increase the expression of the browning genes UCP1 and PRDM16 and the transcription factor C-EBPα, improve the expression and release of the specific factor adiponectin, and inhibit the release of the non-specific factor IL-1β, indicating that aloesin can mediate the browning of 3T3-L1 adipocytes and can be used in the preparation of a product for preventing or treating obesity.